Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin
Aruna Kode, Ioanna Mosialou, Barbara C. Silva, Marie-Therese Rached, Bin Zhou, Ji Wang, Tim M. Townes, Rene Hen, Ronald A. DePinho, X. Edward Guo, Stavroula Kousteni
Aruna Kode, Ioanna Mosialou, Barbara C. Silva, Marie-Therese Rached, Bin Zhou, Ji Wang, Tim M. Townes, Rene Hen, Ronald A. DePinho, X. Edward Guo, Stavroula Kousteni
View: Text | PDF
Research Article Bone biology

FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin

  • Text
  • PDF
Abstract

Serotonin is a critical regulator of bone mass, fulfilling different functions depending on its site of synthesis. Brain-derived serotonin promotes osteoblast proliferation, whereas duodenal-derived serotonin suppresses it. To understand the molecular mechanisms of duodenal-derived serotonin action on osteoblasts, we explored its transcriptional mediation in mice. We found that the transcription factor FOXO1 is a crucial determinant of the effects of duodenum-derived serotonin on bone formation We identified two key FOXO1 complexes in osteoblasts, one with the transcription factor cAMP-responsive element–binding protein 1 (CREB) and another with activating transcription factor 4 (ATF4). Under normal levels of circulating serotonin, the proliferative activity of FOXO1 was promoted by a balance between its interaction with CREB and ATF4. However, high circulating serotonin levels prevented the association of FOXO1 with CREB, resulting in suppressed osteoblast proliferation. These observations identify FOXO1 as the molecular node of an intricate transcriptional machinery that confers the signal of duodenal-derived serotonin to inhibit bone formation.

Authors

Aruna Kode, Ioanna Mosialou, Barbara C. Silva, Marie-Therese Rached, Bin Zhou, Ji Wang, Tim M. Townes, Rene Hen, Ronald A. DePinho, X. Edward Guo, Stavroula Kousteni

×

Figure 8

Model illustrating the mechanism of serotonin/FOXO1 interaction in osteoblasts.

Options: View larger image (or click on image) Download as PowerPoint
Model illustrating the mechanism of serotonin/FOXO1 interaction in osteo...
Under physiological conditions, FOXO1 interacts in the nucleus with both ATF4 and CREB to maintain normal osteoblast proliferation. The association of FOXO1 with ATF4 promotes, whereas the one with CREB suppresses, expression of FOXO1-regulated transcriptional targets. An increase in circulating serotonin levels disrupts the interaction of FOXO1 with CREB. This favors the formation of ATF4-FOXO1 heterodimers. These ATF4-dependent or -independent interactions lead to increased transcriptional activity of FOXO1 and suppression of cell-cycle progression genes. Additionally, following release from its complex with CREB, high levels of available FOXO1 may interact with other transcription factor(s).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts